A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

• Published in: Journal of medical genetics Vol. 46; no. 4; pp. 266 - 271
• Main Authors: Berry-Kravis, E, Hessl, D, Coffey, S, Hervey, C, Schneider, A, Yuhas, J, Hutchison, J, Snape, M, Tranfaglia, M, Nguyen, D V, Hagerman, R
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.04.2009; BMJ Publishing Group; BMJ Publishing Group LTD
• Subjects: Administration, Oral; Adolescent; Adult; Biological and medical sciences; Chromatography, Liquid; Chromosome fragility (bloom syndrome, ataxia telangiectasia, fanconi anemia, x-linked mental retardation...); Convulsions & seizures; Female; Fragile X Syndrome - metabolism; Fragile X Syndrome - physiopathology; Fragile X Syndrome - psychology; Fundamental and applied biological sciences. Psychology; General aspects. Genetic counseling; Genetics of eukaryotes. Biological and molecular evolution; Humans; Imidazoles - administration & dosage; Imidazoles - blood; Imidazoles - pharmacokinetics; Inhibition (Psychology); Male; Mass Spectrometry; Medical genetics; Medical sciences; Molecular and cellular biology; Mutation; Neural Inhibition - drug effects; Neuropsychological Tests; Original; Pharmacokinetics; Pilot Projects; Protein synthesis; Proteins; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate - antagonists & inhibitors; Substance abuse treatment; Vertigo; X chromosomes; Young Adult; Human; Chromosome fragility; Fenobam; Tranquillizer; Psychotropic; Adult; Genetics; Fragile X syndrome; Posology

Objective:A pilot open label, single dose trial of fenobam, an mGluR5 antagonist, was conducted to provide an initial evaluation of safety and pharmacokinetics in adult males and females with fragile X syndrome (FXS).Methods:Twelve subjects, recruited from two fragile X clinics, received a single or...